Anaptysbio Inc ANAB

$48.53 -0.10 (-0.21%)

Valuation

Market cap
1,453,794,000
Revenue TTM
$234,600,000
Net income TTM
$-13,230,000
PE ratio
335.07
Forward PE
—
Profit margin
-5.64%
Debt to equity
0.00

Trading

Volume
441,100
Avg volume
489,634
Day's range
$48.28 – $49.83
Shares out
29,895,000
Stochastic %K
5%
Beta
0.76
Analysts
Strong Sell
Price target
$84.90

Price

Company profile

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular...

Show more

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 362 6295
Website
https://www.anaptysbio.com
Address
10770 Wateridge Circle, Suite 210, San Diego, United States

Latest news

Stocktwits

Quantumup Sep 30, 12:03 PM
Canaccord Genuity🏁 $TRAX and said -- We are initiating coverage of First Tracks Biotherapeutics with a BUY rating and 12-month price target of $50. $ANAB ENTO FBRX TAK SNY TEVA $EPRX AZN BMY PHAT ABBV GILD REGN PFE LLY Canaccord Genuity added—The company, a spin-off from AnaptysBio, has three clinical- stage assets: ANB033, rosnilimab, and ANB101. ANB033 accounts for approximately 95% of our assigned value and is currently being evaluated in two Phase Ib trials, with top-line data expected in celiac disease (CeD) in 4Q26 and 1Q27 and in eosinophilic esophagitis (EoE) in 3Q27. The remaining 5% of our valuation comes from rosnilimab, which recently reported positive Phase IIb data in rheumatoid arthritis but is paused pending a partner for Phase III development.
0 replies
eWhispers Sep 22, 2:05 PM
#earnings moves for Tuesday, September 22, 2026 $AZO $ABVX $THO $ANAB $MLKN
0 replies
Quantumup Sep 22, 1:56 PM
H.C. Wainwright reiterated $ANAB Buy-$95 and said -- Yesterday after the close, Anaptys reported 2Q26 financial results. $GSK $MRK BMY AZN REGN RHHBY ESAIY ABBV Here's what H.C. Wainwright went on to say: https://x.com/Quantumup1/status/2102396343301910697?s=20
0 replies
OpenOutcrier Sep 22, 12:46 PM
$ANAB (+4.3% pre) AnaptysBio Inc (ANAB) Q2 Revenue Beats Estimates; Price-to-Sales Ratio Signals High Growth Expectations https://ooc.bz/l/114907
0 replies
notreload_ai Sep 22, 10:02 AM
$ANAB climbed in premarket after a $27.5M collaboration-revenue beat. Jemperli sales grew 26–34%; ignore the $5.11 EPS tax gain. https://notreload.xyz/xy/revenue-beat-and-packed-calendar-lift-anab-after-earnings/
0 replies
DonCorleone77 Sep 21, 11:44 PM
$ANAB $VICR $BBD $GME AFTER-HOURS MOVERS: Currently Higher After Earnings: - AnaptysBio (ANAB) up 3.4% Currently Also Higher: - Vicor (VICR) up 12.5% after above-consensus pre-announcement - Banco Bradesco S.A. (BBD) up 2.7% after insider buy - GameStop Corp. (GME) up 2.7% after insider buy - Rush Street Interactive (RSI) up 1.1% after being started with a Buy at Stifel Currently Lower: - Valero Energy (VLO) down 0.5% after Jefferies downgrade - Marathon Petroleum (MPC) down 0.6% after Jefferies downgrade
1 replies
StocktwitsEarnings Sep 21, 8:26 PM
$ANAB Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $5.11 up 481.34% YoY • Reported revenue of $27.49M up 23.50% YoY • AnaptysBio continues to expect to achieve $390M in annualized Jemperli royalties payable to the company as early as 2029 at GSKs peak monotherapy sales guidance of $2.7B.
0 replies
ajmrtxl Sep 3, 12:19 PM
$ANAB 's latest data on SqueezeFinder
0 replies